Ann: Chairman's Address to Annual General Meeting, page-15

In recent times, a number of complications have arisen with nuclear reactor produced radiopharmaceuticals, most recently being the outage at the High Flux Reactor (HFR) in Petten, Netherlands, in February 2022. The EU has flagged this as a significant issue and advised that the European research reactors are approaching their “end-of-life”. Without replacing this aging infrastructure, the EU could experience significant radioisotope shortages and impede access to vital treatments for its citizens. These shortages may impact the roll-out of lutetium-177 (177Lu) based products, which will severely hinder the growth of radiopharmaceuticals moving forward."

TLX announcement ....

Upon completion of Stage 1, Telix will have the ability to produce a wide range of medical isotopes, for use in its own commercial and clinical programs, as well as for other organisations. This will include its prostate and kidney cancer imaging agents (TLX591-CDx and TLX250-CDx) and its therapeutic candidates TLX591 and TLX250. The Company has a vision and plan for the site to become a future hub for radiopharmaceutical R&D in Europe, not only for its own programs but through collaborations with partners, including pharmaceutical and biotech companies, hospitals and universities.

furthermore
while Novartis are more interested in therapeutics than imaging - a TLX with manufacturing, and imaging AND therapeutics of their own must be an interesting target ( i do hope this doesnt happen though) . Plus China Grand Pharma all quiet bedding down SRX